Merck (MRK) Income towards Parent Company (2009 - 2026)

Merck (MRK) reported Income towards Parent Company of -$4.2 billion for Q1 2026, down 182.77% year-over-year from $5.1 billion in Q1 2025, and down 242.1% quarter-over-quarter from $3.0 billion in Q4 2025.

Merck (MRK) Income towards Parent Company (2009 - 2026) Analysis & Trends

Merck (MRK) has 17 years of Income towards Parent Company data on file, last reported at -$4.2 billion in Q1 2026.

  • Income towards Parent Company for Q1 2026 came in at -$4.2 billion, down 182.77% year-over-year; the trailing twelve-month figure through Mar 2026 was $9.0 billion (down 48.61% YoY), and the FY2025 annual result was $18.3 billion, up 6.6% from the prior year.
  • Income towards Parent Company slipped to -$4.2 billion in Q1 2026 per MRK's latest filing, from $3.0 billion in the prior quarter.
  • Over five years, Income towards Parent Company peaked at $5.8 billion in Q3 2025 and troughed at -$5.9 billion in Q2 2023.
  • A 4-year average of $2.4 billion and a median of $3.7 billion in 2024 frame the typical range for Income towards Parent Company.
  • The sharpest annual moves came in 2024 and 2026: Income towards Parent Company soared 405.38% in 2024, then slumped 182.77% in 2026.
  • A 4-year view of Income towards Parent Company shows it stood at -$1.2 billion in 2023, then soared by 405.38% to $3.7 billion in 2024, then decreased by 20.89% to $3.0 billion in 2025, then plunged by 242.1% to -$4.2 billion in 2026.
  • Business Quant data shows MRK's Income towards Parent Company at -$4.2 billion in Q1 2026, $3.0 billion in Q4 2025, and $5.8 billion in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Gsk 93,699,046.73 Bn 93,699,041.77 Bn 7.76 Bn
2 Eli Lilly 1,012.06 Bn 1,006.77 Bn 16.22 Bn
3 Johnson & Johnson 560.67 Bn 538.62 Bn 15.96 Bn
4 AbbVie 402.20 Bn 392.85 Bn 10.78 Bn
5 Merck 298.59 Bn 292.94 Bn 12.09 Bn
6 Amgen 188.77 Bn 176.74 Bn 5.87 Bn
7 Gilead Sciences 160.22 Bn 152.49 Bn 5.52 Bn
8 Pfizer 148.19 Bn 135.42 Bn -1.21 Bn
9 Bristol Myers Squibb 116.72 Bn 106.26 Bn 8.07 Bn
10 Novartis Ag 109.78 Bn 109.09 Bn -

Historic Data

Download Data
DateValue
Mar 31, 2026 -4.21 Bn
Dec 31, 2025 2.96 Bn
Sep 30, 2025 5.79 Bn
Jun 30, 2025 4.43 Bn
Mar 31, 2025 5.09 Bn
Dec 31, 2024 3.74 Bn
Sep 30, 2024 3.16 Bn
Jun 30, 2024 5.46 Bn
Mar 31, 2024 4.77 Bn
Dec 31, 2023 -1.23 Bn
Sep 30, 2023 4.75 Bn
Jun 30, 2023 -5.94 Bn
Mar 31, 2023 2.83 Bn
Dec 31, 2021 -62.00 Mn
Jun 30, 2021 332.00 Mn
Mar 31, 2021 437.00 Mn
Dec 31, 2020 523.00 Mn
Sep 30, 2020 617.00 Mn
Jun 30, 2020 661.00 Mn
Mar 31, 2020 3.22 Bn